Sorrento Therapeutics (SRNE) 10-Q 4 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 29, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'SRNE	'
Entity Registrant Name	'Sorrento Therapeutics, Inc.	'
Entity Central Index Key	'0000850261	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	28,932,850

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$44,269	$31,667
Grants and accounts receivables, net	986	394
Prepaid expenses and other, net	586	571
Total current assets	45,841	32,632
Property and equipment, net	2,360	2,440
Intangibles, net	31,563	33,321
Goodwill	24,041	24,041
Other, net	324	148
Total assets	104,129	92,582
Current liabilities:	'	'
Accounts payable	1,489	2,154
Accrued payroll and related	1,157	1,663
Current portion of deferred compensation	975	904
Accrued expenses	1,428	385
Current portion of debt	3,655	374
Total current liabilities	8,704	5,480
Long-term debt	8,446	4,431
Deferred compensation	1,639	1,497
Deferred tax liabilities	14,248	14,248
Deferred rent and other	102	117
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding	0	0
Common stock, $0.0001 par value; 750,000,000 shares authorized and 28,532,850 and 23,028,100 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	3	2
Additional paid-in capital	130,000	99,668
Accumulated deficit	-59,013	-32,861
Total stockholders' equity	70,990	66,809
Total liabilities and stockholders' equity	$104,129	$92,582

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	28,532,850	23,028,100
Common stock, shares outstanding	28,532,850	23,028,100

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Grant	$147	$83	$329	$359
Sales and services	1,129	0	2,698	0
Total revenues	1,276	83	3,027	359
Operating costs and expenses:	'	'	'	'
Costs of revenues	527	0	1,600	0
Research and development	5,440	2,082	16,856	5,622
Acquired in-process research and development	0	0	209	1,210
General and administrative	1,854	1,114	7,600	3,752
Intangible amortization	586	194	1,758	313
Total costs and operating expenses	8,407	3,390	28,023	10,897
Loss from operations	-7,131	-3,307	-24,996	-10,538
Interest expense	-476	-51	-1,167	-83
Interest income	2	2	11	6
Net loss	($7,605)	($3,356)	($26,152)	($10,615)
Net loss per share - basic and diluted	($0.27)	($0.24)	($1.02)	($0.80)
Weighted average number of shares during the period - basic and diluted	28,533	14,135	25,682	13,304

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]
In Thousands, except Share data
Balance at Dec. 31, 2013	$66,809	$2	$99,668	($32,861)
Balance, shares at Dec. 31, 2013	'	23,028,100	'	'
Issuance of common stock for research agreement	209	0	209	0
Issuance of common stock for research agreement, shares	'	25,000	'	'
Issuance of common stock warrants in connection with amended loan and security agreement	322	0	322	0
Stock-based compensation	3,159	0	3,159	0
Issuance of common stock for cash	26,643	1	26,642	0
Issuance of common stock for cash, shares	'	5,479,750	'	'
Net loss	-26,152	0	0	-26,152
Balance at Sep. 30, 2014	$70,990	$3	$130,000	($59,013)
Balance, shares at Sep. 30, 2014	'	28,532,850	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014
Statement Of Stockholders Equity [Abstract]	'
Issuance of common stock per share	$5.25
Common stock issuance cost	$2,126

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($26,152)	($10,615)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'
Depreciation and amortization	2,372	638
Non-cash interest expense	331	35
Stock-based compensation and issuance of warrants	3,159	622
Acquired in-process research and development	209	0
Provision for doubtful accounts	9	0
Changes in operating assets and liabilities:	'	'
Grants and other receivables	-601	43
Prepaid expenses and other	-254	-348
Accounts payable	-703	824
Accrued expenses and other liabilities	522	-477
Net cash used for operating activities	-21,108	-9,278
Investing activities	'	'
Purchases of property and equipment	-433	-359
Purchase of intangible assets	0	-511
Cash received in connection with Mergers	0	126
Net cash provided by (used for) investing activities	-433	-744
Financing activities	'	'
Proceeds from issuance of common stock, net of issuance costs	26,643	6,354
Net borrowings under debt agreements	7,500	5,000
Proceeds from exercise of stock options	0	7
Net cash provided by financing activities	34,143	11,361
Net change in cash and cash equivalents	12,602	1,339
Cash and cash equivalents at beginning of period	31,667	5,091
Cash and cash equivalents at end of period	44,269	6,430
Cash paid during the period for:	'	'
Income taxes	6	1
Interest paid	$636	$48

Nature_of_Operations_Summary_o

Nature of Operations, Summary of Significant Accounting Policies and Business Activities	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations, Summary of Significant Accounting Policies and Business Activities	'
	1. Nature of Operations, Summary of Significant Accounting Policies and Business Activities
	Nature of Operations and Basis of Presentation
	Sorrento Therapeutics, Inc. (NASDAQ: SRNE), together with its wholly-owned subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the U.S., Europe and additional international markets. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. The Company’s pipeline consists of its lead oncology product candidate Cynviloq™, a micellar paclitaxel formulation, resiniferatoxin (or RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, as well as fully human therapeutic antibodies derived from its proprietary G-MAB® library platform and antibody drug conjugates, or ADCs. In addition, the Company generates revenues from the sale of customized reagents and providing contract development services.
	As of September 30, 2014, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure, and had not realized revenues from its planned principal operations.
	The accompanying interim consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with United States generally accepted accounting principles (GAAP). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries; IgDraSol, Inc., or IgDraSol; Sherrington Pharmaceuticals, Inc., or Sherrington; Concortis Biosystems, Corp., or Concortis; Ark Animal Health, Inc., or Ark; and Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong, which was registered effective December 4, 2012. Sherrington and Sorrento Hong Kong had no operating activity through September 2014. All intercompany balances and transactions have been eliminated in consolidation.
	The balance sheet at December 31, 2013 is derived from the audited consolidated financial statements at that date which are not presented herein.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2014 fiscal year.
	Liquidity
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) completes its bioequivalence, or BE, registration trial related to Cynviloq and prepares for its New Drug Application filing anticipated in 2015, (ii) advances RTX into clinical trials and potentially pursues other human indications, (iii) funds Ark activities in anticipation of Ark securing stand-alone financing, (iv) continues to identify a number of potential mAb and ADC drug candidates and further advances various preclinical development activities, (v) continues development of, and seeks regulatory approvals for, its product candidates, and begin to commercialize any approved products, and (vi) expands corporate infrastructure, including the costs associated with being a NASDAQ listed public company.
	In May 2014, the Company closed an underwritten public offering of 4,765,000 shares of common stock, at $5.25 per share, and in June 2014, closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 714,750 shares of its common stock, with total gross proceeds of $28.8 million, before underwriting discounts and commissions and other offering expenses payable by the Company.
	In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12,500 from $5,000, with the same two banks, which was funded at closing. The interest rate on the amended and restated loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the Term Loan maturity date of September 30, 2017. Management believes the Company has the ability to meet all obligations due over the course of the next twelve months.
	The Company plans to continue to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013. The Shelf Registration Statement provides the Company the ability to offer up to $100 million of securities, including equity and other securities as described in the registration statement. After the May 2014 underwritten offering (see Note 6), the Company has the ability to offer up to $36.6 million of additional securities. Pursuant to the Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2014 and December 31, 2013, the carrying amount of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Grants and Accounts Receivable
	Grants receivable at September 30, 2014 and December 31, 2013 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
	Accounts receivable at September 30, 2014 and December 31, 2013 consists of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of September 30, 2014 and December 31, 2013, the allowance for doubtful accounts was $9 and $0, respectively.
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
	Acquisitions and Intangibles
	The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
	Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of transfer of the rights to the Company in April 2013. Amortization expense for the three months ended September 30, 2014 and 2013 was $1 each. Amortization expense for the nine months ended September 30, 2014 and 2013 was $4 and $3, respectively, all such costs have been included in intangibles amortization.
	License rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years from the date of acquisition of the rights in September 2013. Amortization expense for the three months ended September 30, 2014 and 2013 was $475 and $111, respectively. Amortization expense for the nine months ended September 30, 2014 and 2013 was $1,425 and $111, respectively, which has been included in intangibles amortization.
	Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of acquisition of the technology in December 2013. Amortization expense for the three and nine months ended September 30, 2014 was $44 and $132, respectively, which has been included in intangibles amortization.
	Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition in December 2013. Amortization expense for the three and nine months ended September 30, 2014 was $66 and $198, respectively, which has been included in intangibles amortization.
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through September 30, 2014.
	Goodwill
	Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing at least annually or when a triggering event is identified that could indicate a potential impairment. We test our goodwill annually, or quarterly when events or changes in circumstances warrant, for impairment in the fourth quarter of each year. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the market value of the Company. No impairment to the carrying value of this goodwill has been identified from the acquisition date through September 30, 2014.
	Revenue Recognition
	The Company’s grant revenues are generated primarily from three NIH and two U.S. Department of Treasury (or U.S. Treasury) grant awards and a feasibility study agreement, or the Collaboration Agreement entered into with a third party in July 2010, and from revenues generated from sales and services from the sale of customized reagents and providing contract development services. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
	Revenues from sales and services are generated from the sale of customized reagents and providing contract development services. Reagents are used for preparing ADCs, these reagents include industrial standard cytotoxins, linkers, and linker-toxins. The contract development services include providing synthetic expertise to customer’s synthesis by delivering them proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers. Revenue is recognized when, (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured.
	The Company is obligated to accept from customers the return of products sold that are damaged or don’t meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
	Acquired In-Process Research and Development Expense
	The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use.
	Research and Development Costs and Collaborations
	All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
	Income Taxes
	The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions.
	The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
	The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually. As of September 30, 2014, the Company maintained a full valuation allowance against its deferred tax assets.
	Stock-based Compensation
	The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest.
	Net Loss per Share
	Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss per share includes the impact of potentially dilutive securities. No dilutive effect was calculated for the three and nine months ended September 30, 2014 and 2013 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. The Company had outstanding common share equivalents of 2,091,826 and 551,850 at September 30, 2014 and 2013, respectively.
	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive loss. For the three and nine months ended September 30, 2014 and 2013, the comprehensive loss was equal to the net loss.
	New Accounting Standards
	In May 2014, Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts with Customers” (Topic 606). The guidance of this Update effects any entities that either issues contracts with customers or transfer goods or services or enters into contracts for the transfer of non-financial assets. The core principal of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve those core principals, the ASU specifies steps that the entity should apply for revenue recognition. The guidance also specifies the accounting for some costs to obtain or fulfill the contract with customer and disclosure requirements to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU No. 2014-09 is effective for annual reporting period beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company is currently evaluating the potential impact that adoption may have on its consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-10 “Development Stage Entities” (Topic 915). The objective of the ASU is to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements for development stage entities. The ASU removes all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the inception-to-date information and certain other disclosures. The ASU also eliminates an exception provided to development stage entities in Topic 810 “Consolidation” for determining whether an entity is a variable interest entity on the basis of amount of investment equity at risk. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Earlier adoption is permitted for any annual or interim period for which financial statements have not yet been issued. The Company has adopted Topic 915 effective with the filing of its Form 10-Q as of and for the three and nine months ended September 30, 2014.
	In August 2014, the FASB issued ASU No. 2014-15 "Disclosures of Uncertainties About an Entity's Ability to Continue as a Going Concern". The new standard provides guidance which requires management to evaluate whether conditions or events raise substantial doubt about the entity’s ability to continue as a going concern and, if so, to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Significant_Agreements_and_Con

Significant Agreements and Contracts	9 Months Ended
	Sep. 30, 2014
Significant Agreements And Contracts [Abstract]	'
Significant Agreements and Contracts	'
	2. Significant Agreements and Contracts
	License Agreement with The Scripps Research Institute
	In January 2010, the Company entered into a license agreement, or the TSRI License, with The Scripps Research Institute, or TSRI. Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus (“Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved, (iii) agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days’ notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For the three months ended September 30, 2014 and 2013, the Company recorded $41 and $13 in patent prosecution and maintenance costs associated with the TSRI License, respectively. For the nine months ended September 30, 2014 and 2013, the Company recorded $97 and $20 in patent prosecution and maintenance costs associated with the TSRI License, respectively. All such costs have been included in general and administrative expenses.
	The fair value of the warrants to purchase Company common stock, issued in connection with the TSRI License, of $18 was determined using the Black-Scholes valuation model with the following weighted-average assumptions: risk-free interest rate of 2.48%, no dividend yield, expected term of 10 years, and volatility of 102%. Such fair value has been included in general and administrative expenses for the three and nine month periods ended September 30, 2014.
	NIH Grants
	In July 2011, the NIAID awarded the Company a second Advanced Technology Small Business Technology Transfer Research (STTR) grant to support the Company’s program to generate and develop antibody therapeutics and vaccines to combat C. difficile infections, or the C. difficile Grant award. The project period for the Phase I C. difficile Grant award covered a two-year period which commenced in June 2011 and ended in June 2013, with the total grant award of $600. During the three months ended September 30, 2014 and 2013, the Company recorded no revenue associated with the C. difficile Grant award. During the nine months ended September 30, 2014 and 2013, the Company recorded $0 and $144 of revenue associated with the C. difficile Grant award, respectively.
	In June 2012, the NIAID awarded the Company a third Advanced Technology STTR grant to support the Company’s program to generate and develop novel human antibody therapeutics to combat Staph infections, including Methicillin-resistant Staph, or the Staph Grant II award. The project period for the Phase I grant covers a two-year period which commenced in June 2012, with a total grant award of $600. During the three months ended September 30, 2014 and 2013, the Company recorded $0 and $84 of revenue associated with the Staph Grant II award, respectively. During the nine months ended September 30, 2014 and 2013 the Company recorded $150 and $216 of revenue associated with the Staph Grant II award, respectively.
	In June 2014, the NIAID awarded the Company a Phase II STTR grant to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staphylococcus aureus (S. aureus or Staph) infections, including methicillin-resistant S. aureus (MRSA), or the Staph Grant III award. The project period for this Phase II grant covers a two-year period which commenced in June 2014, with total funds available of approximately $1 million per year for up to 2 years. During the three and nine months ended September 30, 2014, the Company recorded $115 and $147 of revenue, respectively, associated with the Staph Grant III award.
	In June 2014, the NIAID awarded the Company a Phase I STTR grant entitled “Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery”. This grant will support the preclinical development of novel anti-Pseudomonas aeruginosa mAb immunotherapy or an antibody-mediated targeted antibiotic delivery vehicle. Each modality may be an effective and safe stand-alone therapy and/or a component of a “cocktail” therapeutic option for prevention and treatment of P. aeruginosa infections. The project period for this Phase I grant covers a two-year period which commenced in July 2014, with total funds available of approximately $300 per year for up to 2 years. During the three and nine months ended September 30, 2014, the Company recorded $11 of revenue associated with the Phase I STTR grant award.
	In July 2014, the National Cancer Institute (NCI), a division of the NIH, awarded the Company a Phase I STTR grant, entitled “Targeting of Myc-Max Dimerization for the Treatment of Cancer”. This grant will support the preclinical development of the Myc inhibitor, which interferes with the protein-protein interaction (PPI) between Myc and its obligatory dimerization partner, Max, preventing sequence-specific binding to DNA and subsequent initiation of oncogenic transformation. The project period for this Phase I grant covers a one-year period which commenced in August 2014, with total funds available of approximately $225. During the three and nine months ended September 30, 2014, the Company recorded $19 of revenue associated with the Phase I Myc grant award.
	In August 2014, the National Heart, Lung, and Blood Institute (NHBLI), a division of the NIH awarded the Company a Phase I Small Business Technology Transfer (SBIR) grant entitled “Human Anti-WISP-1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis”. This grant will advance the Company’s immunotherapy targeting WNT-1 Inducible Signaling Protein-1(WISP1) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). WISP1 is a protein that has been shown to be upregulated in IPF, linked to key growth factors, cellular proliferation, hyperplasia and is correlated with late stage cancers. IPF is a fatal disease which results in progressive loss of lung function due to fibrosis of the lungs. The project period for this Phase I grant covers a one-year period which commenced in August 2014, with total funds available of approximately $225.  During the three and nine months ended September 30, 2014, the Company recorded $2 of revenue associated with the Phase I WISP1 grant award.

Mergers_and_Acquisitions

Mergers and Acquisitions	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Mergers and Acquisitions	'
	3. Mergers and Acquisitions
	On March 7, 2013, the Company entered into various agreements with IgDraSol, a private company focused on the development of Cynviloq, an oncologic agent for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers, as follows: (i) an exclusive option agreement, (ii) an asset purchase agreement pursuant to which the Company agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies, and (iii) an initial services agreement, pursuant to which, IgDraSol is to provide certain product development and technology services related to the Company’s antibody platform.
	On September 9, 2013, the Company exercised its option to acquire IgDraSol whereby IgDraSol became a wholly-owned subsidiary and the Company acquired all rights to Cynviloq. Pursuant to the merger agreement, the Company issued 3,006,641 shares of common stock to IgDraSol stockholders and paid $382 in cash. Upon the later achievement of a specified regulatory milestone, the Company will issue an additional 1,306,272 shares of common stock to former IgDraSol stockholders. The Company’s lead compound is Cynviloq, a micellar paclitaxel formulation drug product. Cynviloq is currently approved and marketed in several countries, including South Korea for MBC and NSCLC under the trade name Genexol-PM®. The Company licensed exclusive distribution rights for Cynviloq in North America, the 27 countries of the European Union, and Australia, from Samyang Biopharmaceuticals Corporation, a South Korean corporation.
	On October 9, 2013, the Company entered into an Agreement and Plan of Merger and Reorganization and acquired privately-held Sherrington in exchange for 200,000 shares of its common stock, for an aggregate purchase price of $1,698 which was recognized as acquired in-process research and development expense. Sherrington is focused on the development of a treatment for intractable pain in end-stage disease. RTX is a novel, non-opiate, small molecule that permanently eliminates pain experienced by end-stage cancer patients when directly interacting with the nerve cells. RTX is currently being tested in an investigator-sponsored Phase I/II clinical trial under a Cooperative Research and Development Agreement. To date, 10 patients with terminal cancer pain have been treated at the NIH. The Company intends to launch additional trials to rapidly advance clinical development of the drug in patients with terminal cancer pain.
	On December 19, 2013, the Company acquired and merged with privately-held Concortis, whereby Concortis became a wholly-owned subsidiary. Upon closing, the Company issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Certain Concortis employees and consultants received $1,000 in compensation for the year ending December 31, 2013, and are to receive annual deferred compensation payments totaling $1,000 on December 31 for each of the years ending 2014, 2015, and 2016. The net present value of the deferred compensation payments was calculated using the effective interest method, and is included in the purchase price. The total transaction is valued at $14.7 million. Concortis has proprietary cytotoxic payloads as well as C-lock® and K-lock® conjugation technologies that allow for site-specific toxin conjugation to the antibody. These next generation technologies may improve the overall stability and potency of the ADCs. First-generation conjugation technologies lead to inconsistent drug-antibody ratios, which result in a heterogeneous mixture of ADCs. This variability has been a constraining factor in unlocking the full therapeutic potential for current-generation ADCs. The ADC technology complements the Company’s existing development programs, particularly its G-MAB® antibody library and related monoclonal antibodies. Concortis uses its proprietary technologies to provide various customized reagents as well as drug conjugation services to customers in the pharmaceutical industry.
	The IgDraSol, Sherrington and Concortis acquisitions have been accounted for in accordance with the acquisition method of accounting under FASB ASC Topic 805, “Business Combinations” (“Topic 805”). Topic 805 requires, among other things, that identifiable assets acquired and liabilities assumed be recognized at their fair values which are based in part on third party appraisals as of the Acquisition Date. Under the acquisition method of accounting, the purchase consideration was allocated to the assets acquired, including tangible assets and other identifiable intangible assets and liabilities assumed, based on their estimated fair market values on the date of acquisition. Any excess purchase price after the initial allocation to identifiable net tangible and identifiable intangible assets was assigned to goodwill. These completed acquisitions have been accounted for as purchases and the results of operations have been included in the consolidated financial statements since their respective dates of acquisition.
	The following unaudited pro forma consolidated financial information summarizes the combined results of operations for the Company as though the IgDraSol, Sherrington and Concortis acquisitions occurred as of January 1, 2013. The unaudited pro forma financial information for all periods presented also includes the business combination accounting effects resulting from these acquisitions including amortization charges from acquired intangible assets. The unaudited pro forma financial information as presented below is for informational purposes only and does not purport to be indicative of the results of operations for future periods or the results what actually would have been realized had the entities been a single entity during these periods. The unaudited pro forma combined results are presented in thousands, except share and per share information.
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2014			2013			2014			2013
		As Reported			Pro Forma			As Reported			Pro Forma
	Total Revenues	$	1,276		$	1,246		$	3,027		$	2,807
	Loss from operations	$	(7,131	)	$	(5,299	)	$	(24,996	)	$	(18,280	)
	Net loss	$	(7,605	)	$	(5,476	)	$	(26,152	)	$	(18,655	)
	Net loss per share-basic and diluted	$	(0.27	)	$	(0.29	)	$	(1.02	)	$	(1.05	)

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	4. Goodwill
	In connection with the acquisitions of IgDraSol, Sherrington and Concortis, the Company generated goodwill of $24,041.

Loan_and_Security_Agreement

Loan and Security Agreement	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Loan and Security Agreement	'
	5. Loan and Security Agreement
	In September 2013, the Company entered into a $5,000 loan and security agreement with two banks pursuant to which: (i) the lenders provided the Company a term loan which was funded at closing, (ii) the Company repaid its then outstanding equipment loan balance of $762, and (iii) the lenders received a warrant to purchase an aggregate 31,250 shares of the Company’s common stock at an exercise price of $8.00 per share exercisable for seven years from the date of issuance. The value of the warrants, totaling $215, was recorded as debt discount and additional paid-in capital.
	In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12,500 from $5,000, with the same two banks. Such loan was funded at closing and is secured by a lien covering substantially all of the Company’s assets, excluding intellectual property, which is subject to a negative pledge. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the loan maturity date of September 30, 2017. The amended and restated loan: (i) interest rate is 7.95% per annum, and (ii) provided the Lenders additional warrants to purchase an aggregate of 34,642 shares of the Company’s common stock at an exercise price of $12.99 per share, exercisable for seven years from the date of issuance. The value of the warrants, totaling $322, was recorded as debt discount and additional paid-in capital.
	At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $781.
	The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt. In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.
	Long-term debt and unamortized discount balances are as follows (in thousands):
	Face value of amended and restated loan	$	12,500
	Fair value of all warrants		(536	)
	Accretion of debt discount		137
	Balance at September 30, 2014	$	12,101
	Future minimum payments under the amended and restated loan and security agreement are as follows:
	Year Ending December 31,
	2014	$	1,174
	2015		4,697
	2016		4,697
	2017		4,304
	Total future minimum payments		14,872
	Unamortized interest		(2,372	)
	Debt discount		(399	)
	Total minimum payment		12,101
	Current portion		(3,655	)
	Long-term debt	$	8,446

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	6. Stockholders’ Equity
	Common Stock
	In January 2014, the Company entered into a research agreement and issued 25,000 shares of common stock valued at $209.
	In May 2014, the Company closed an underwritten public offering of 4,765,000 shares of common stock, at $5.25 per share, and in June 2014, closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 714,750 shares of its common stock, with total gross proceeds of $28.8 million, before underwriting discounts and commissions and other offering expenses of $2.1 million payable by the Company.
	Purchase Warrants
	Concurrent with the October 30, 2013 offering, the Company agreed to issue and sell to the underwriters a warrant (“Underwriters Warrant”) for the purchase of an aggregate of 182,600 shares of common stock, for a nominal amount. The Underwriters Warrant agreement is exercisable, in whole or in part, commencing on a date which is one (1) year after the effective date of the Registration Statement and expiring on the five-year anniversary of the effective date of the Registration Statement at an initial exercise price per share of common stock of $9.0625, which is equal to 125% of the initial public offering price of $7.25 per share.
	Convertible Promissory Notes
	In October 2013, the Company issued an aggregate $1,850 principal amount of Notes that bear interest at 7% per annum. Concurrently with the closing of the public offering, such Notes and related accrued interest totaling $7 automatically converted into 256,119 shares of common stock.
	Stock Incentive Plans
	2009 Equity Incentive Plan
	In February 2009, the Company’s Board of Directors approved the 2009 Equity Incentive Plan, or the EIP, under which 400,000 shares of common stock were reserved for issuance to employees, non-employee directors and consultants of the Company. In March 2009, the Company issued 296,154 restricted common stock awards to certain consultants for aggregate gross proceeds of less than $1, of which the Company repurchased 44,166 unvested shares of restricted common stock for a nominal amount in January 2011. The restricted shares vest monthly over four years and all remaining shares were fully vested as of September 30, 2014. No further shares are available for grant under the EIP.
	2009 Non-Employee Director Grants
	In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved the reservation and issuance of 8,000 nonstatutory stock options to the Company’s non-employee directors. The outstanding options vested on the one year anniversary of the vesting commencement date in October 2010, and are exercisable for up to 10 years from the grant date. No further shares may be granted under this plan and, as of September 30, 2014, 3,200 options were outstanding.
	2009 Stock Incentive Plan
	In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan. In June 2014, the Company’s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan, or the Stock Plan, to increase the number of common stock authorized to be issued pursuant to the Stock Plan to 3,760,000. Such shares of the Company’s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants will generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. Stock options are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of the Company’s common stock issued in connection with an early exercise however, may be repurchased by the Company upon termination of the optionee’s service with the Company.
	During the nine months ended September 30, 2014 and 2013, the Company’s Board of Directors awarded 1,088,500 and 110,200 options to certain employees, directors and consultants, respectively. As of September 30, 2014 and 2013, 1,905,366 and 833,400 shares were available for grant under the Stock Plan, respectively. See Note 8.
	The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock based compensation expense is recognized over the vesting period using the straight-line method. The fair value of employee stock options was estimated at the grant date using the following assumptions:
		Nine months ended
		September 30,
		2014			2013
	Dividend yield		—			—
	Volatility		78	%		109	%
	Risk-free interest rate		1.95	%		1.19	%
	Expected life of options	6.1 years			6.1 years
	The weighted average grant date fair value per share of employee stock options granted during the nine months ended September 30, 2014 and 2013 was $8.05 and $4.78, respectively.
	The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the United States Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.
	The total employee stock-based compensation recorded as operating expenses was $490, and $158 for the three months ended September 30, 2014 and 2013, respectively. The total employee stock-based compensation recorded as operating expenses was $2,619 and $454 for the nine months ended September 30, 2014 and 2013, respectively.
	As of September 30, 2014, unrecognized compensation cost related to the options was $5,260 which will be recognized over 3.0 years.
	The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the applicable authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $136 and $34 for the three months ended September 30, 2014 and 2013, respectively. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $540 and $167 for the nine months ended September 30, 2014 and 2013, respectively.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	7. Income Taxes
	The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development. The net deferred tax asset has been fully offset by a valuation allowance because of the Company’s history of losses. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

Related_Party_Agreements_and_O

Related Party Agreements and Other - Ark	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Agreements and Other - Ark	'
	8. Related Party Agreements and Other – Ark
	License and Development Agreement
	On June 18, 2014, the Company and Ark entered into a License and Development Agreement (LDA) whereby the Company granted Ark a license to develop and commercialize RTX for animal use only, in exchange for the issuance to the Company of 10,000,000 shares of Ark common stock valued at $13,100, representing 100% of the outstanding shares of Ark common stock. Such intercompany transactions have been eliminated in consolidation.
	Transition Services Agreement
	On June 18, 2014, the Company entered into a Transition Services Agreement (TSA) with Ark which became effective retroactively to April 1, 2014. Under the TSA, the Company has provided and/or has made available to Ark various administrative, financial, legal, insurance, facility, information technology, laboratory, real estate and other services to be provided by, or on behalf of, the Company, together with such other services as reasonably requested by Ark. In consideration for such services, Ark will pay fees to the Company for the services provided, and those fees will generally be in amounts intended to allow the Company to recover all of its direct and indirect costs incurred in providing such services. The personnel performing services under the TSA are employees and/or independent contractors of the Company and are not under the direction or control of Ark. These personnel costs are based upon the actual percentages of time spent by Company personnel performing services for Ark under the TSA. In addition, Ark will reimburse the Company for direct out-of-pocket costs incurred by the Company for third party services provided to Ark. Through September 30, 2014, the Company has recorded $757 of costs associated with activities contemplated under the TSA.
	In order for the Company to be reimbursed by Ark for activities provided under the TSA, Ark must be successful in raising financing on a stand-alone basis. There can be no assurance that Ark will be successful in securing third party financing.
	Loan and Security Agreement
	On June 18, 2014, the Company and Ark entered into a Loan and Security Agreement (Loan Agreement) pursuant to which the Company agreed to lend Ark, as amended in August 2014, up to $1,000 for working capital purposes. Advances under the Loan Agreement bear interest at six percent (6%) per annum. Outstanding advances mature on the earlier of: (i) following the consummation of any public or private offering of securities in which Ark receives gross proceeds of at least $5,000, (ii) an event of default under the Loan Agreement, or (iii) June 18, 2015. In connection with the Loan Agreement, the Company has a security interest in all of Ark’s assets, including Ark’s intellectual property, until the loan is repaid in full. During the period from Ark’s inception in February 2014 through September 30, 2014, the Company paid for certain general, administrative and research and development expenses totaling $757. The intercompany balances associated with these transactions have been eliminated in consolidation.
	2014 Stock Option Plan
	In May 2014, Ark adopted the Ark 2014 Stock Option Plan and reserved and awarded 600,000 options to certain directors and consultants under such plan. Stock options granted under such plan typically vest after four years of continuous service from the grant date and will have a contractual term of ten years. No further shares may be granted under this plan and, as of September 30, 2014, 600,000 options were outstanding.
	The total employee and consultant stock-based compensation recorded as operating expenses for the three and six months ended September 30, 2014 was $89 and $378, respectively. Total unrecognized stock-based compensation expense related to unvested stock option grants for both directors and consultants as of September 30, 2014 was $30, and the weighted-average period over which these grants are expected to vest is approximately eight months.
	The weighted-average assumptions used in the Black-Scholes option pricing model used to determine the fair value of stock option grants were as follows: expected dividend yield – 0%, risk-free interest rate – 1.94% to 2.53%, expected volatility – 75% to 78%, and expected term of 6.08 to 10 years.
	2014 Equity Incentive Plan
	In May 2014, Ark adopted the 2014 Equity Incentive Plan. Under this plan Ark may grant equity awards which include stock options, restricted stock units and stock appreciation rights. Ark has reserved for future issuance 1,000,000 shares of common stock issuable pursuant to this plan. The plan’s share reserve, as defined, will automatically increase each year commencing on January 1, 2015, in an amount equal to 3.0% of the total number of shares outstanding on the last day of the preceding calendar year. No equity awards have been issued under the plan as of September 30, 2014.
	Related Party Transactions
	During the nine months ended September 30, 2014, the Company purchased products totaling $439 from Levena Biopharma Co., LTD (Levena), a Chinese Corporation.  The Company’s Chief Technology Officer is also one of the owners of Levena.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	9. Subsequent Events
	On October 3, 2014, the Company entered into an exclusive license and development agreement (the “License Agreement”) with China Oncology Focus Limited, an affiliate of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharma”) pursuant to which Lee’s Pharma has licensed the Company’s fully human, immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 (“STI-A1014”). Under the terms of the License Agreement, Lee’s Pharma received exclusive rights to develop and commercialize STI-A1014 for the greater Chinese market, including Mainland China, Hong Kong, Macau, and Taiwan. In turn, the Company will receive an up-front payment of $1.0 million, potential future milestone payments and royalties which range from 5% to 10% on future net sales. In total, the Company has the potential to receive more than $46 million upon the successful attainment of key milestones, excluding royalties, and retains all the rights to use data generated by Lee’s Pharma for territories outside of the greater Chinese market. Additionally, Lee’s Pharma purchased 400,000 common shares of the Company at a price of $9.00 per share, for gross proceeds of $3.6 million.
	On October 30, 2014, the Company entered into a second amendment to its amended and restated loan and security agreement which extended the interest only period from October 1, 2014 to May 1, 2015, after which equal monthly payments of principal and interest are due until the loan maturity date of September 30, 2017.  See Note 5.

Nature_of_Operations_Summary_o1

Nature of Operations, Summary of Significant Accounting Policies and Business Activities (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations and Basis of Presentation	'
	Nature of Operations and Basis of Presentation
	Sorrento Therapeutics, Inc. (NASDAQ: SRNE), together with its wholly-owned subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the U.S., Europe and additional international markets. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. The Company’s pipeline consists of its lead oncology product candidate Cynviloq™, a micellar paclitaxel formulation, resiniferatoxin (or RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, as well as fully human therapeutic antibodies derived from its proprietary G-MAB® library platform and antibody drug conjugates, or ADCs. In addition, the Company generates revenues from the sale of customized reagents and providing contract development services.
	As of September 30, 2014, the Company had devoted substantially all of its efforts to product development, raising capital and building infrastructure, and had not realized revenues from its planned principal operations.
	The accompanying interim consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with United States generally accepted accounting principles (GAAP). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries; IgDraSol, Inc., or IgDraSol; Sherrington Pharmaceuticals, Inc., or Sherrington; Concortis Biosystems, Corp., or Concortis; Ark Animal Health, Inc., or Ark; and Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong, which was registered effective December 4, 2012. Sherrington and Sorrento Hong Kong had no operating activity through September 2014. All intercompany balances and transactions have been eliminated in consolidation.
	The balance sheet at December 31, 2013 is derived from the audited consolidated financial statements at that date which are not presented herein.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2014 fiscal year.
Liquidity	'
	Liquidity
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) completes its bioequivalence, or BE, registration trial related to Cynviloq and prepares for its New Drug Application filing anticipated in 2015, (ii) advances RTX into clinical trials and potentially pursues other human indications, (iii) funds Ark activities in anticipation of Ark securing stand-alone financing, (iv) continues to identify a number of potential mAb and ADC drug candidates and further advances various preclinical development activities, (v) continues development of, and seeks regulatory approvals for, its product candidates, and begin to commercialize any approved products, and (vi) expands corporate infrastructure, including the costs associated with being a NASDAQ listed public company.
	In May 2014, the Company closed an underwritten public offering of 4,765,000 shares of common stock, at $5.25 per share, and in June 2014, closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 714,750 shares of its common stock, with total gross proceeds of $28.8 million, before underwriting discounts and commissions and other offering expenses payable by the Company.
	In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12,500 from $5,000, with the same two banks, which was funded at closing. The interest rate on the amended and restated loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the Term Loan maturity date of September 30, 2017. Management believes the Company has the ability to meet all obligations due over the course of the next twelve months.
	The Company plans to continue to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013. The Shelf Registration Statement provides the Company the ability to offer up to $100 million of securities, including equity and other securities as described in the registration statement. After the May 2014 underwritten offering (see Note 6), the Company has the ability to offer up to $36.6 million of additional securities. Pursuant to the Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2014 and December 31, 2013, the carrying amount of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Grants and Accounts Receivable	'
	Grants and Accounts Receivable
	Grants receivable at September 30, 2014 and December 31, 2013 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
	Accounts receivable at September 30, 2014 and December 31, 2013 consists of trade receivables from sales and services provided to certain customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts. As of September 30, 2014 and December 31, 2013, the allowance for doubtful accounts was $9 and $0, respectively.
Property and Equipment	'
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
Acquisitions and Intangibles	'
	Acquisitions and Intangibles
	The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
	Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of transfer of the rights to the Company in April 2013. Amortization expense for the three months ended September 30, 2014 and 2013 was $1 each. Amortization expense for the nine months ended September 30, 2014 and 2013 was $4 and $3, respectively, all such costs have been included in intangibles amortization.
	License rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years from the date of acquisition of the rights in September 2013. Amortization expense for the three months ended September 30, 2014 and 2013 was $475 and $111, respectively. Amortization expense for the nine months ended September 30, 2014 and 2013 was $1,425 and $111, respectively, which has been included in intangibles amortization.
	Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of acquisition of the technology in December 2013. Amortization expense for the three and nine months ended September 30, 2014 was $44 and $132, respectively, which has been included in intangibles amortization.
	Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition in December 2013. Amortization expense for the three and nine months ended September 30, 2014 was $66 and $198, respectively, which has been included in intangibles amortization.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through September 30, 2014.
Goodwill	'
	Goodwill
	Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing at least annually or when a triggering event is identified that could indicate a potential impairment. We test our goodwill annually, or quarterly when events or changes in circumstances warrant, for impairment in the fourth quarter of each year. We are organized as a single reporting unit and perform impairment testing by comparing the carrying value of the reporting unit to the market value of the Company. No impairment to the carrying value of this goodwill has been identified from the acquisition date through September 30, 2014.
Revenue Recognition	'
	Revenue Recognition
	The Company’s grant revenues are generated primarily from three NIH and two U.S. Department of Treasury (or U.S. Treasury) grant awards and a feasibility study agreement, or the Collaboration Agreement entered into with a third party in July 2010, and from revenues generated from sales and services from the sale of customized reagents and providing contract development services. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
	Revenues from sales and services are generated from the sale of customized reagents and providing contract development services. Reagents are used for preparing ADCs, these reagents include industrial standard cytotoxins, linkers, and linker-toxins. The contract development services include providing synthetic expertise to customer’s synthesis by delivering them proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers. Revenue is recognized when, (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured.
	The Company is obligated to accept from customers the return of products sold that are damaged or don’t meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
Acquired In-Process Research and Development Expense	'
	Acquired In-Process Research and Development Expense
	The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use.
Research and Development Costs and Collaborations	'
	Research and Development Costs and Collaborations
	All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
Income Taxes	'
	Income Taxes
	The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions.
	The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
	The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually. As of September 30, 2014, the Company maintained a full valuation allowance against its deferred tax assets.
Stock-based Compensation	'
	Stock-based Compensation
	The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest.
Net Loss per Share	'
	Net Loss per Share
	Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss per share includes the impact of potentially dilutive securities. No dilutive effect was calculated for the three and nine months ended September 30, 2014 and 2013 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. The Company had outstanding common share equivalents of 2,091,826 and 551,850 at September 30, 2014 and 2013, respectively.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive loss. For the three and nine months ended September 30, 2014 and 2013, the comprehensive loss was equal to the net loss.
New Accounting Standards	'
	New Accounting Standards
	In May 2014, Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts with Customers” (Topic 606). The guidance of this Update effects any entities that either issues contracts with customers or transfer goods or services or enters into contracts for the transfer of non-financial assets. The core principal of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve those core principals, the ASU specifies steps that the entity should apply for revenue recognition. The guidance also specifies the accounting for some costs to obtain or fulfill the contract with customer and disclosure requirements to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU No. 2014-09 is effective for annual reporting period beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company is currently evaluating the potential impact that adoption may have on its consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-10 “Development Stage Entities” (Topic 915). The objective of the ASU is to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements for development stage entities. The ASU removes all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the inception-to-date information and certain other disclosures. The ASU also eliminates an exception provided to development stage entities in Topic 810 “Consolidation” for determining whether an entity is a variable interest entity on the basis of amount of investment equity at risk. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Earlier adoption is permitted for any annual or interim period for which financial statements have not yet been issued. The Company has adopted Topic 915 effective with the filing of its Form 10-Q as of and for the three and nine months ended September 30, 2014.
	In August 2014, the FASB issued ASU No. 2014-15 "Disclosures of Uncertainties About an Entity's Ability to Continue as a Going Concern". The new standard provides guidance which requires management to evaluate whether conditions or events raise substantial doubt about the entity’s ability to continue as a going concern and, if so, to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Mergers_and_Acquisitions_Table

Mergers and Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Unaudited Pro Forma Combined Results	'
	The unaudited pro forma combined results are presented in thousands, except share and per share information.
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2014			2013			2014			2013
		As Reported			Pro Forma			As Reported			Pro Forma
	Total Revenues	$	1,276		$	1,246		$	3,027		$	2,807
	Loss from operations	$	(7,131	)	$	(5,299	)	$	(24,996	)	$	(18,280	)
	Net loss	$	(7,605	)	$	(5,476	)	$	(26,152	)	$	(18,655	)
	Net loss per share-basic and diluted	$	(0.27	)	$	(0.29	)	$	(1.02	)	$	(1.05	)

Loan_and_Security_Agreement_Ta

Loan and Security Agreement (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-Term Debt and Unamortized Discount Balances	'
	Long-term debt and unamortized discount balances are as follows (in thousands):
	Face value of amended and restated loan	$	12,500
	Fair value of all warrants		(536	)
	Accretion of debt discount		137
	Balance at September 30, 2014	$	12,101
Future Minimum Payments under Amended and Restated Loan and Security Agreement	'
	Future minimum payments under the amended and restated loan and security agreement are as follows:
	Year Ending December 31,
	2014	$	1,174
	2015		4,697
	2016		4,697
	2017		4,304
	Total future minimum payments		14,872
	Unamortized interest		(2,372	)
	Debt discount		(399	)
	Total minimum payment		12,101
	Current portion		(3,655	)
	Long-term debt	$	8,446

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Fair Value of Employee Stock Options	'
	The fair value of employee stock options was estimated at the grant date using the following assumptions:
		Nine months ended
		September 30,
		2014			2013
	Dividend yield		—			—
	Volatility		78	%		109	%
	Risk-free interest rate		1.95	%		1.19	%
	Expected life of options	6.1 years			6.1 years

Nature_of_Operations_Summary_o2

Nature of Operations, Summary of Significant Accounting Policies and Business Activities - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	31-May-14	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Oct. 30, 2013	Jul. 31, 2013
		Bank	Bank	Bank	Bank
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Common stock price per share	$5.25	'	'	'	'	'	$7.25	'
Gross proceeds from common stock issuance	$28,800,000	'	'	$26,643,000	$6,354,000	'	'	'
Principal amount of loan agreement	'	12,500,000	5,000,000	12,500,000	5,000,000	'	'	'
Number of banks provided term loan	'	2	2	2	2	'	'	'
Interest rate	'	7.95%	'	7.95%	'	'	'	'
Term loan maturity date	'	'	'	30-Sep-17	'	'	'	'
Maximum amount of equity and other securities authorized to offer	'	'	'	'	'	'	'	100,000,000
Remaining amount of equity and other securities authorized to offer	36,600,000	'	'	'	'	'	'	'
Allowance for doubtful accounts	'	9,000	'	9,000	'	0	'	'
Impairment losses of long-lived assets	'	'	'	0	'	'	'	'
Impairment of carrying value of goodwill	'	'	'	0	'	'	'	'
Uncertain tax positions	'	0	'	0	'	'	'	'
Common stock outstanding	'	2,091,826	551,850	2,091,826	551,850	'	'	'
Dilutive effect	'	0	0	0	0	'	'	'
Patents [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Estimated useful lives of assets	'	'	'	'19 years	'	'	'	'
Amortization expense	'	1,000	1,000	4,000	3,000	'	'	'
License rights [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Estimated useful lives of assets	'	'	'	'15 years	'	'	'	'
Amortization expense	'	475,000	111,000	1,425,000	111,000	'	'	'
Technologies [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Estimated useful lives of assets	'	'	'	'19 years	'	'	'	'
Amortization expense	'	44,000	'	132,000	'	'	'	'
Customer relationships [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Estimated useful lives of assets	'	'	'	'5 years	'	'	'	'
Amortization expense	'	$66,000	'	$198,000	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Estimated useful lives of fixed assets	'	'	'	'3 years	'	'	'	'
Maximum [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Estimated useful lives of fixed assets	'	'	'	'5 years	'	'	'	'
Underwritten public offering [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Issuance of common stock	4,765,000	'	'	'	'	'	'	'
Over-allotment option [Member]	'	'	'	'	'	'	'	'
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Issuance of common stock	714,750	'	'	'	'	'	'	'

Significant_Agreements_and_Con1

Significant Agreements and Contracts - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2012
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Terminate notice of license	'	'	'60 days	'	'
Fair value of the warrants to purchase Company common stock, issued	$18	'	$18	'	'
Weighted-average assumptions, risk-free interest rate	'	'	2.48%	'	'
Weighted-average assumptions, dividend yield	'	'	0.00%	'	'
Expected term of warrants	'	'	'10 years	'	'
Warrants volatility	'	'	102.00%	'	'
Revenue grant as related costs and expenses incurred	147	83	329	359	'
General and administrative expenses [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Patent prosecution and maintenance costs	41	13	97	20	'
C Difficile Grant Award [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Period of grant	'	'	'2 years	'	'
Revenue grant as related costs and expenses incurred	'	'	0	144	'
Award of grant received for phase 1	600	'	600	'	'
Staph Grant II Award [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Period of grant	'	'	'2 years	'	'
Revenue grant as related costs and expenses incurred	0	84	150	216	'
Award of grant received for phase 1	'	'	'	'	600
Staph Grant III Award [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Period of grant	'	'	'2 years	'	'
Revenue grant as related costs and expenses incurred	115	'	147	'	'
Award of grant received for phase 1	1,000	'	1,000	'	'
Pseudomonas aeruginosa infections [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Period of grant	'	'	'2 years	'	'
Revenue grant as related costs and expenses incurred	11	'	11	'	'
Award of grant received for phase 1	300	'	300	'	'
Myc Grant I Award [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Period of grant	'	'	'1 year	'	'
Revenue grant as related costs and expenses incurred	19	'	19	'	'
Total available fund	225	'	225	'	'
WISP1 Grant I Award [Member]	'	'	'	'	'
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Period of grant	'	'	'1 year	'	'
Award of grant received for phase 1	2	'	2	'	'
Total available fund	$225	'	$225	'	'

Mergers_and_Acquisitions_Addit

Mergers and Acquisitions - Additional Information (Detail) (USD $)	1 Months Ended	0 Months Ended		9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Oct. 09, 2013	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
	IgDraSol, Inc. [Member]	Sherrington Pharmaceuticals, Inc. [Member]	Sherrington Pharmaceuticals, Inc. [Member]	Concortis Biosystems, Corp. [Member]	Concortis Biosystems, Corp. [Member]
			Patient
Business Acquisition [Line Items]	'	'	'	'	'
Number of share issued for acquisition	3,006,641	200,000	'	1,331,978	'
Cash payment in connection with IgDraSol merger	$382	'	'	'	'
Additional shares of common stock issued	1,306,272	'	'	'	'
Total purchase price	'	1,698	'	14,700	'
Number of patients treated with terminal cancer pain	'	'	10	'	'
Bonus paid in 2013	'	'	'	'	1,000
Bonus payable in 2014	'	'	'	1,000	'
Bonus payable in 2015	'	'	'	1,000	'
Bonus payable in 2016	'	'	'	$1,000	'

Mergers_and_Acquisitions_Sched

Mergers and Acquisitions - Schedule of Unaudited Pro Forma Combined Results (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Acquisition Pro Forma Information [Abstract]	'	'	'	'
Total Revenues	$1,276	$1,246	$3,027	$2,807
Loss from operations	-7,131	-5,299	-24,996	-18,280
Net loss	($7,605)	($5,476)	($26,152)	($18,655)
Net loss per share-basic and diluted	($0.27)	($0.29)	($1.02)	($1.05)

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Goodwill	$24,041	$24,041

Loan_and_Security_Agreement_Ad

Loan and Security Agreement - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2014
	Bank	Bank
Debt Instrument [Line Items]	'	'
Principal amount of loan agreement	$5,000	'
Number of banks provided term loan	2	2
Repayment of outstanding equipment loan balance	762	'
Warrant received to purchase aggregate of common stock - shares	31,250	34,642
Warrant received to purchase aggregate of common stock - exercise price	$8	$12.99
Exercisable period for warrants	'7 years	'7 years
Debt discount	'	536
Amended and restated principal amount of loan agreement	5,000	12,500
Term loan maturity date	'	30-Sep-17
Interest rate	'	7.95%
Minimum percentage of pre-payment fees	'	1.00%
Maximum percentage of pre-payment fees	'	3.00%
Final fee	'	781
Loan and security agreement [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt discount	'	215
Amended loan and security agreement [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt discount	'	$322

Loan_and_Security_Agreement_Sc

Loan and Security Agreement - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Face value of amended and restated loan	$12,500
Fair value of all warrants	-536
Accretion of debt discount	137
Balance at September 30, 2014	$12,101

Loan_and_Security_Agreement_Fu

Loan and Security Agreement - Future Minimum Payments under Amended and Restated Loan and Security Agreement (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
2014	$1,174	'
2015	4,697	'
2016	4,697	'
2017	4,304	'
Total future minimum payments	14,872	'
Unamortized interest	-2,372	'
Debt discount	-399	'
Total minimum payment	12,101	'
Current portion	-3,655	-374
Long-term debt	$8,446	$4,431

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock) (Detail) (USD $)	1 Months Ended			9 Months Ended
In Thousands, except Share data, unless otherwise specified	31-May-14	Jan. 31, 2014	Oct. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Oct. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Number of shares issued for purchase of patent rights	'	25,000	'	'	'	'
Value of common stock issued for purchase of patent rights	'	$209	'	'	'	'
Common stock price per share	$5.25	'	'	'	'	$7.25
Number of additional common shares granted to purchase under over-allotment option	714,750	'	'	'	'	'
Gross proceeds from common stock issuance	28,800	'	'	26,643	6,354	'
Common stock issuance cost	2,126	'	'	2,126	'	'
Initial exercise price per share of common stock under warrants	'	'	'	$9.06	'	'
Exercise price of warrants to percentage of initial public offering price of shares	'	'	'	125.00%	'	'
Aggregate principal amount of Convertible Promissory Notes	'	'	'	12,500	'	'
Interest rate	'	'	'	7.95%	'	'
Accrued interest	'	'	7	'	'	'
Debt converted into common stock	'	'	256,119	'	'	'
Convertible Promissory Notes [Member]	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Aggregate principal amount of Convertible Promissory Notes	'	'	$1,850	'	'	'
Interest rate	'	'	7.00%	'	'	'
Underwriters [Member]	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Number of common shares to be purchased under warrants	'	'	'	182,600	'	'
Warrant agreement exercisable and expiration description	'	'	'	'Warrant agreement is exercisable, in whole or in part, commencing on a date which is one (1) year after the effective date of the Registration Statement and expiring on the five-year anniversary of the effective date of the Registration Statement	'	'
Underwritten public offering [Member]	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Underwritten public offering shares of common stock	4,765,000	'	'	'	'	'

Stockholders_Equity_Stock_Ince

Stockholders' Equity (Stock Incentive Plans) (Detail) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Feb. 28, 2009

Mar. 31, 2009

Mar. 31, 2009

Jan. 31, 2011

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

In Thousands, except Share data, unless otherwise specified

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Non-Employee Director Grants [Member]

2009 Non-Employee Director Grants [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Unvested Restricted Stock [Member]

Outstanding Options [Member]

Outstanding Options [Member]

Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance

'

'

'

400,000

'

'

'

'

8,000

'

'

'

'

'

Shares issued to consultants under 2009 equity incentive plan

'

'

'

'

296,154

'

'

'

'

'

'

'

'

'

Aggregate gross proceeds

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

Unvested shares of restricted common stock repurchased by the company

'

'

'

'

'

'

44,166

'

'

'

'

'

'

'

Restricted shares vesting period under 2009 equity incentive plan

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'3 years

Outstanding options vesting anniversary period

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

Maximum term of options granted under stock plan

'

'

'

'

'

'

'

'10 years

'

'

'

'10 years

'

'

Shares available for grant

'

'

'

'

'

'

'

0

'

1,905,366

833,400

1,905,366

833,400

'

Option outstanding

'

'

'

'

'

'

'

3,200

'

'

'

'

'

'

Common stock, shares authorized

750,000,000

750,000,000

'

'

'

'

'

'

'

3,760,000

'

3,760,000

'

'

Employee option grants vested

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

Stock options vesting rights under 2009 stock incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'Employee option grants will generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years.

Options awarded to employees and consultant

'

'

'

'

'

'

'

'

'

'

'

1,088,500

110,200

'

Weighted average fair value per share of employee stock options granted

'

'

'

'

'

'

'

'

'

'

'

$8.05

$4.78

'

Employee stock-based compensation recorded as operating expenses

'

'

'

'

'

'

'

'

'

490

158

2,619

454

'

Unrecognized compensation cost related to the employee options

'

'

'

'

'

'

'

'

'

5,260

'

5,260

'

'

Period for recognized compensation cost

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

Stock-based compensation for non-employees

'

'

'

'

'

'

'

'

'

$136

$34

$540

$167

'

Stockholders_Equity_Fair_Value

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) (Employee Stock Option [Member])	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Employee Stock Option [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Dividend yield	0.00%	0.00%
Volatility	78.00%	109.00%
Risk-free interest rate	1.95%	1.19%
Expected life of options	'6 years 1 month 6 days	'6 years 1 month 6 days

Related_Party_Agreements_and_O1

Related Party Agreements and Other - Ark - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended		1 Months Ended	3 Months Ended	9 Months Ended			1 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 18, 2014	Sep. 30, 2014	Dec. 31, 2013	31-May-14	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	31-May-14	Sep. 30, 2014	Jun. 18, 2014
				2014 Stock Option Plan [Member]	2014 Stock Option Plan [Member]	2014 Stock Option Plan [Member]	2014 Stock Option Plan [Member]	2014 Stock Option Plan [Member]	2014 Equity Incentive Plan [Member]	2014 Equity Incentive Plan [Member]	License and Development Agreement [Member]
							Minimum [Member]	Maximum [Member]
Schedule Of Other Related Party Transactions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock, shares issued	'	28,532,850	23,028,100	'	'	'	'	'	'	'	10,000,000
Common shares value, related party agreement	'	$3	$2	'	'	'	'	'	'	'	$13,100
Percentage of outstanding common shares of Ark	'	'	'	'	'	'	'	'	'	'	100.00%
Costs associated with related party agreements	'	757	'	'	'	'	'	'	'	'	'
Loan for catering working capital purposes	1,000	'	'	'	'	'	'	'	'	'	'
Percentage of interest rate on advances under loan agreement	6.00%	'	'	'	'	'	'	'	'	'	'
Gross proceeds received by related party	5,000	'	'	'	'	'	'	'	'	'	'
Options awarded to employees	'	'	'	600,000	'	'	'	'	'	'	'
Stock options, vesting period	'	'	'	'4 years	'	'	'	'	'	'	'
Stock options, contractual term	'	'	'	'10 years	'	'	'	'	'	'	'
Shares available for grant	'	'	'	0	'	'	'	'	'	0	'
Stock options, outstanding	'	'	'	'	600,000	600,000	'	'	'	'	'
Employee stock-based compensation recorded as operating expenses	'	'	'	'	89	378	'	'	'	'	'
Unrecognized compensation cost related to the employee options	'	'	'	'	30	30	'	'	'	'	'
Weighted average period, grants are expected to vest	'	'	'	'	'	'8 months	'	'	'	'	'
Method used to determine the fair value of stock option	'	'Black-Scholes option pricing model	'	'	'	'	'	'	'	'	'
Dividend yield	'	'	'	'	'	0.00%	'	'	'	'	'
Risk-free interest rate, minimum	'	'	'	'	'	1.94%	'	'	'	'	'
Risk-free interest rate, maximum	'	'	'	'	'	2.53%	'	'	'	'	'
Expected volatility, minimum	'	'	'	'	'	75.00%	'	'	'	'	'
Expected volatility, maximum	'	'	'	'	'	78.00%	'	'	'	'	'
Expected life of options	'	'	'	'	'	'	'6 years 29 days	'10 years	'	'	'
Common stock reserved for issuance	'	'	'	'	'	'	'	'	1,000,000	'	'
Percentage increase in outstanding shares	'	'	'	'	'	'	'	'	3.00%	'	'
Related party, products purchases	'	$439	'	'	'	'	'	'	'	'	'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended			0 Months Ended
	31-May-14	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Oct. 03, 2014	Oct. 03, 2014	Oct. 03, 2014
					Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
						Minimum [Member]	Maximum [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'
License agreement, up-front payment to be received	'	'	'	'	$1,000,000	'	'
License agreement, potential milestone and royalties as percentage on future net sales	'	'	'	'	'	5.00%	10.00%
Maximum Milestone Receivables	'	'	'	'	46,000,000	'	'
Common stock, shares issued	'	28,532,850	'	23,028,100	400,000	'	'
Sale of Stock, Price Per Share	'	'	'	'	$9	'	'
Gross proceeds from common stock issuance	$28,800,000	$26,643,000	$6,354,000	'	$3,600,000	'	'
Term loan maturity date	'	30-Sep-17	'	'	'	'	'